Filters
Among pregnant women, early initiation of low-dose aspirin largely reduces the incidence of pre-eclampsia and related neonatal outcomes without increasing the risk of bleeding, according to a meta-analysis.
Higher muscular and performance fitness* is inversely associated with the incidence of hearing loss, with a clear dose-response particularly with vertical jump height and single-leg balance, the Niigata Wellness Study has shown.
Excision with narrow margins does not predict mortality or recurrence in patients with Merkel cell carcinoma, results of a study have shown. Residual tumour, found primarily on deep surgical margins, is independently associated with prognosis.
Extremes of age, comorbid conditions, and elevated C-reactive protein (CRP) are associated with severe COVID-19 in children, according to a study.
Use of an in-clinic outpatient pharmacy appears to result in better retention in care and clinical outcomes among people living with HIV (PLWH), according to a study.
Fast-track cardiac anaesthesia (FTCA) using a combination of remifentanil and dexmedetomidine is effective and safe for the transthoracic device closure of atrial septal defect (ASD) in children, according to a new study.
Daily treatment with liraglutide in individuals with obesity yields significant weight loss without deleterious events, as shown in a study from South Korea.
Triple therapy with ursodeoxycholic acid, obeticholic acid, and fibrates leads to normalization of biochemical liver tests and pruritus improvement in patients with difficult‐to‐treat primary biliary cholangitis, as shown in a study.
Kidney transplant recipients with low serum bilirubin levels are at greater risk of adverse outcomes, such as graft loss, graft failure, and all-cause mortality, a recent study has found.
In the treatment of patients with gram-positive hospital-acquired or ventilator-associated bacterial pneumonia, tedizolid works as well as linezolid in terms of 28-day all-cause mortality but not investigator-assessed clinical response, according to the results of a phase III trial.
